HealthDay, Amanda Gardner
Many people have pinned their hopes on human genome scans as the cornerstone of the rapidly emerging field of personalized medicine, able to predict the future health of individuals.
But there may be limits to what information whole genome sequencing can provide, according to new research slated for presentation Monday at the American Association for Cancer Research annual meeting in Chicago. The study will be simultaneously published online in Science Translational Medicine.
"In most cases, genome sequencing is not going to tell people what disease they're going to get or die from. It can be valuable in telling what diseases they have an excess risk for," said study co-author Dr. Bert Vogelstein, director of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins University in Baltimore. . .View Full Article
Notable Quotes
"I think GALE has a good shot on its phase 3 NeuVax trial." (5/23/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Echo He More >
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"ATHX is a neat little company that has a great management team and deep science bench." (5/10/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >
Personal Gene Mapping Has Its Limits
Source: HealthDay, Amanda Gardner (4/2/12)
"The costs of whole genome sequencing are plummeting, making the test more accessible to more people, yet the ability of the test to provide useful information to patients has not been studied quantitatively."
More Experts
"NEO is a small but focused diagnostic company with numerous competitive advantages." (4/4/13) NeoGenomics Laboratories - The Life Sciences Report Interview with Grant Zeng More >
"The Abstral acquisition has transformed GALE from a development biotech company into a commercial organization." (4/4/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Grant Zeng More >
"I believe the monoclonal antibody technology that SYN is working on for pertussis is especially interesting." (3/28/13) Synthetic Biologics Inc. - The Life Sciences Report Interview with Keith Markey More >
"ATHX has one of the best manufacturing processes in allogeneic cell therapy I've ever seen." (3/14/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"If phase 2b ASSURE trial results show a significant decrease in atherosclerotic plaque volume, it will be a huge win for RVX." (3/7/13) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico More >
The Life Sciences Report